Optimized Rhombic Experimental Dynamic Checkerboard Designs to Elucidate Pharmacodynamic Drug Interactions of Antibiotics.

checkerboard design drug interaction testing optimized experimental design stochastic simulation and estimation synergy

Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 10 06 2022
accepted: 09 09 2022
pubmed: 28 9 2022
medline: 27 12 2022
entrez: 27 9 2022
Statut: ppublish

Résumé

Quantification of pharmacodynamic interactions is key in combination therapies, yet conventional checkerboard experiments with up to 10 by 10 combinations are labor-intensive. Therefore, this study provides optimized experimental rhombic checkerboard designs to enable an efficient interaction screening with significantly reduced experimental workload. Based on the general pharmacodynamic interaction (GPDI) model implemented in Bliss Independence, a novel rhombic 'dynamic' checkerboard design with quantification of bacteria instead of turbidity as endpoint was developed. In stochastic simulations and estimations (SSE), the precision and accuracy of interaction parameter estimations and classification rates of conventional reference designs and the newly proposed rhombic designs based on effective concentrations (EC) were compared. Although a conventional rich design with 20-times as many combination scenarios provided estimates of interaction parameters with higher accuracy, precision and classification rates, the optimized rhombic designs with one natural growth scenario, three monotherapy scenarios per combination partner and only four combination scenarios were still superior to conventional reduced designs with twice as many combination scenarios. Additionally, the rhombic designs were able to identify whether an interaction occurred as a shift on maximum effect or EC50 with > 98%. Overall, effective concentration-based designs were found to be superior to traditional standard concentrations, but were more challenged by strong interaction sizes exceeding their adaptive concentration ranges. The rhombic designs proposed in this study enable a reduction of resources and labor and can be a tool to streamline higher throughput in drug interaction screening.

Identifiants

pubmed: 36163408
doi: 10.1007/s11095-022-03396-7
pii: 10.1007/s11095-022-03396-7
pmc: PMC9780134
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3267-3277

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : 16GW0249K
Organisme : Agence nationale de la recherche, France
ID : R19094GG

Informations de copyright

© 2022. The Author(s).

Références

J Biomed Inform. 2001 Oct;34(5):348-64
pubmed: 12123152
Pharm Res. 2015 Jul;32(7):2410-8
pubmed: 25630818
Proc Biol Sci. 2018 Jun 13;285(1880):
pubmed: 29899074
J Biopharm Stat. 2020;30(1):31-45
pubmed: 31032703
Stat Methods Med Res. 2020 Mar;29(3):934-952
pubmed: 31131705
AAPS J. 2018 Jun 21;20(4):77
pubmed: 29931471
Nat Commun. 2017 Dec 14;8(1):2129
pubmed: 29242552
J Clin Microbiol. 2005 Jan;43(1):140-3
pubmed: 15634962
Nat Rev Microbiol. 2019 Mar;17(3):141-155
pubmed: 30683887
Comput Methods Programs Biomed. 2001 May;65(2):141-51
pubmed: 11275334
J Clin Microbiol. 2014 Dec;52(12):4124-8
pubmed: 24920779

Auteurs

Niklas Kroemer (N)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.

Romain Aubry (R)

Inserm U1070, Poitiers, France.
Université de Poitiers, UFR de Médecine Pharmacie, Poitiers, France.

William Couet (W)

Inserm U1070, Poitiers, France.
Université de Poitiers, UFR de Médecine Pharmacie, Poitiers, France.
CHU de Poitiers, Laboratoire de Toxicologie-Pharmacologie, Poitiers, France.

Nicolas Grégoire (N)

Inserm U1070, Poitiers, France.
Université de Poitiers, UFR de Médecine Pharmacie, Poitiers, France.
CHU de Poitiers, Laboratoire de Toxicologie-Pharmacologie, Poitiers, France.

Sebastian G Wicha (SG)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany. sebastian.wicha@uni-hamburg.de.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Humans China Cerebral Hemorrhage Patient Care Bundles Length of Stay

Classifications MeSH